The long-awaited results from the PRECISION trial are in — with some caveats. Physicians have been awaiting these results since 2005 when the U.S. Food and Drug Administration called for a heart-safety clinical trial after a string of related drugs were pulled from the market. A small number of cardiovascular events suggested that celecoxib could lead to cardiovascular disease risk at high doses. The randomized, multi-center, double-blind, 10-year trial published in the New England Journal of Medicine on Nov. 13, shows that naproxen and ibuprofen at high doses are no safer than moderate doses of prescription-only celecoxib (Celebrex). In this slideshow, we summarize the results.
The trial was sponsored by Pfizer.
Steven E. Nissen, M.D., et al. "Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis," New England Journal of Medicine. Nov. 13, 2016. DOI: 10.1056/NEJMoa1611593